Clozapine serum concentrations in dopamimetic psychosis in Parkinson's disease and related disorders

European Journal of Clinical Pharmacology

Volumn 70, Issue 12, 2014, Pages 1471-1476

  Lutz, Ulrich C ^a,b   Sirfy, Ahmad ^a,c   Wiatr, Gerlinde ^a   Altpaß, Danuta ^a   Farger, Gisbert ^a   Gasser, Thomas ^d   Karle, Kathrin N ^d   Batra, Anil ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Psychiatric Hospital   (Germany)

^c Department of Surgery   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Clozapine; High performance liquid chromatography (HPLC); Parkinson's disease; Psychosis; Therapeutic drugmonitoring (TDM)

Indexed keywords

CLOZAPINE; NORCLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL STUDY; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DOPAMIMETIC PSYCHOSIS; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER FAILURE; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHARMACOLOGICAL PARAMETERS; PSYCHOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT INDICATION; TREATMENT RESPONSE; BLOOD; MIDDLE AGED; PSYCHOTIC DISORDERS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 84919924693     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1772-0     Document Type: Article

References (30)

1. Von Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol 15:473-490
2. Friedman JH (2010) Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord 16:553-560
3. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R, The Parkinson Study Group (2003) Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60:1756-1761
4. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, Basile G, Di Raimondo G, La Spina P, Quattrone A (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 27:153-156
5. Pollak P, Tison F, Rascol O, Destée A, Péré JJ, Senard JM, Durif F, Bourdeix I (2004) Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiat 75:689-695
6. Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S (2007) Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur Neuropsychopharmacol 17:165-171
7. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D (1997) Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 48:1077-1081
8. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 52:438-445
9. Zoldan J, Friedberg G, Livneh M, Melamed E (1995) Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45:1305-1308
10. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2010) Pimavanserin, a serotonin 2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 35:881-892
11. Gareri P, De Fazio P, Russo E, Marigliano N, De Fazio S, De Sarro G (2008) The safety of clozapine in the elderly. ExpertOpin Drug Saf 7: 525-538
12. Gaertner I, Gaertner HJ, Vonthein R, Dietz K (2001) Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21:305-310
13. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Fric M, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Jaquenoud Sirot E, Kirchherr H, Laux G, Lutz UC, Messer T, Müller MJ, Pfuhlmann B, Rambeck B, Riederer P, Schoppek B, Stingl J, Uhr M, Ulrich S, Waschgler R, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44:195-235
14. Xiang YQ, Zhang ZJ, Wenig YZ, Zhai YM, Li WB, Cai ZJ, Tan QR, Wang CY (2006) Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophr Res 83:201-210
15. Couchman L, Morgan PE, Spencer EP, Flanagan RJ (2010) Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 32:438-447
16. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H (1989) Dose-related plasma levels of clozapine: influence of smoking behavior, sex and age. Psychopharmacol (Berl) 99:S38-S40
17. Stratton MA, Salinas RC (2003) Medication management in the elderly. J Okla State Med Assoc 96:116-122
18. Buurma H, De Smet PA, Egberts AC (2006) Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions. Drug Saf 29:723-732
19. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. a high potency effect of clozapine. Neuropsychopharmacology 12:39-45
20. Stevens I, Mahal A, Gaertner HJ (1995) Clozapin-plasmaspiegel bei der akuttherapie von schizophrenen patienten. Klinische Bedeutung Psychopharmakotherapie 2:77-81
21. Gaertner I, Gaertner HJ, Vonthein R, Dietz K (2001) Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21:305-310
22. Thomas AA, Friedman JH (2010) Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol 33: 14-16
23. Ackenheil M, Bräu H, Burkhart A, Franke A, Pacha W (1976) Antipsychotic efficacy in relation to plasma levels of clozapine (author's transl). Arzneimittelforschung 26:1156-1158
24. Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A, Cassano GB, Lucacchini A, Martini C, Dell'Osso L (2002) Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 26:473-480
25. Corsonello A, Pedone C, Incalzi RA (2010) Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 17:571-584
26. Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, Eap CB (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319-326
27. Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, Folan MM, Condifer KA (1999) Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol 39:936-940
28. Walker AA, Dickmann L, Isoherranen N (2011) Pregnancy decreases rat CYP1A2 activity and expression. Drug Metab Dispos 39:4-7
29. Isoherranen N, Thummel KE (2013) Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 41:256-262
30. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799-812